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Abstract
Objectives Enamel matrix derivative (EMD) has been suc-
cessfully used for the regeneration of periodontal tissues in-
cluding new cementum, periodontal ligament, and alveolar
bone. Combination of EMD with bone grafting materials has
however generated variable clinical results. Recently, we have
demonstrated that a new formulation of EMD in a liquid car-
rier system (Osteogain®) has improved physicochemical
properties for the adsorption of EMD to a bone grafting ma-
terial. The aim of the present study was to investigate the
regenerative potential of Osteogain®, in combination with a
bone graft, on new bone formation in a rat femur defect model.
Materials and methods Fifty-four critically sized femur de-
fects (3 mm in diameter) were created bilaterally in 27 rats
and treated following the group allocation: (1) drilled unfilled
control, (2) a natural bone mineral (NBM), and (3) NBM +
Osteogain®. All defects were histologically analyzed at 2, 4,
and 8 weeks after surgical intervention. Micro-CT analysis,
hematoxylin and eosin (H&E) staining, and Safranin O stain-
ing were performed to quantify new bone formation.
Results Significantly more new bone formation was observed
in defects treated with NBM + Osteogain® at both 4 and
8 weeks when compared to NBM alone and the control un-
filled defects (P<0.05). Histologically, the formation of more
mature mineralized bone with the presence of osteocytes were
found more commonly in defects treated with Osteogain® +
NBM at 8 weeks post-healing when compared to NBM alone.
Conclusions The present study demonstrate that Osteogain®
in combination with a bone grafting material improves the
speed and quality of new bone formation in rat osseous
defects.
Clinical relevance Future clinical research are now warranted
to fully characterize the benefits of Osteogain®, a new formu-
lation of enamel matrix proteins delivered in liquid formation
when used in combination with a bone grafting material.
Keywords Enamelmatrix derivative (EMD) . Emdogain .
Natural bonemineral . BioOss . Bone graftingmaterials
Introduction
One modality that has been used to manage a variety of peri-
odontal disorders is the use of an enamel matrix derivative
(EMD) harvested from developing porcine teeth [1–4]. It has
previously been shown that the proteins found in EMD have a
significant influence on cell behavior of many cell types by
mediating cell attachment, spreading, proliferation, and sur-
vival, as well as expression of transcription factors, growth
factors, cytokines, extracellular matrix constituents, and other
molecules involved in the regulation of bone remodeling [5].
Amelogenin is the major component of EMD, a family of
hydrophobic proteins that account for over 95 % of the total
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protein content [6]. Other proteins that exist in the enamel
matrix include enamelin, ameloblastin (also called amelin or
sheathlin), amelotin, apin, and various proteinases [7, 8].
For years, EMD has been packaged in a polyglycolic acid
(PGA) carrier under the trademark name Emdogain®. In order
to improve the regenerative potential of Emdogain®, various
attempts have been made to combine it with a bone grafting
material to prevent flap collapse and improve blood clot sta-
bility [9].While a variety of clinical trials have shown positive
effects for a combination of Emdogain® + grafting material
when compared to treatment with either Emdogain® alone or
grafting materials alone, others have failed to show such an
advantage [9–16].
Recent research from our laboratory has demonstrated that
the adsorption of EMD to bone grafting material varies sig-
nificantly between grafting materials [17]. Furthermore, the
use of Emdogain®, although ideal for root surface adsorption,
displayed drastically increased thickness of coating of enamel
matrix proteins to the bone grafting surface which were easily
dissolved following a simple PBS rinse. Contrarily, the use of
EMD in a liquid formulation exhibited more favorable surface
coating by demonstrating (a) an increase and more complete
surface loading of porous graft materials and (b) tighter and
more stable surface coating with enamel matrix proteins [17].
The physicochemical properties of EMD were then modified
to deliver it through stable liquid formulation, specifically for
combination with bone grafting particles, with better adsorp-
tion properties (Wangnerud et al. 2015, currently under re-
view). This new formulation of EMD, called Osteogain®,
demonstrates similar effects on osteoblast and periodontal lig-
ament (PDL) cell proliferation and differentiation when com-
pared to Emdogain®. Furthermore, its combination with a
bone grafting material increased a wide variety of osteoblast
transcription factors, differentiation factors, cytokines, and
proteins when compared to bone grafting material alone
(Miron et al. 2015, currently in review).
Thus, the aim of the present study was to investigate the
regenerative potential of Osteogain® when combined with a
bone grafting material on bone defects. Femur defects created
in rats were filled with either a natural bone mineral (NBM)




Twenty-seven male Wistar rats (8 weeks of age, 180–200-g
weight) were used. All animal handling and surgical proce-
dures were in accordance with the policies of the Ethics
Committee for Animal Research, Wuhan University, China
(ethical approval number 2011038). The animals were housed
in individual wire cages in a temperature- and humidity-
controlled room (20–25 °C and 60±5 % relative humidity)
with a 12-h light/dark cycle and allowed food and water ad
libitum. All animals were allowed to acclimate with the labo-
ratory environment for 1 week before surgical procedures
were carried out. All operations were carried out under sterile
conditions with gentle surgical techniques. The animals were
administered intramuscular injections of penicillin (NCPC;
400,000 IU/ml, 0.1 ml/kg day) at the time of surgery and once
daily for the next 3 days. No significant pre-operation or post-
operation fractures were produced.
Femur defect drilling was performed under general anes-
thesia by intraperitoneal injection of sodium pentobarbital
(Merck, Darmstadt, Germany; 40 mg/kg body weight) as pre-
viously described [18–20]. A linear skin incision of approxi-
mately 1 cm in the distal femoral epiphysis was made bilater-
ally, and blunt dissection of the muscles was performed to
expose the femoral condyle [21, 22]. Then, a 2.2-mm-diame-
ter anteroposterior bicortical channel was created perpendicu-
lar to the shaft axis to remove cancellous bone, by using a
trephine bur at a slow speed irrigated under saline solution
to avoid thermal necrosis. The drilled holes were rinsed with
saline solution in order to remove bone fragments from the
cavity. An equal amount of implant materials (0.1 g per hole)
was then gently placed to fill the grilled defects according to
group allocation: drilled control, NBM, and NBM +
Osteogain®, respectively. The concentration of enamel matrix
proteins (EMPs) for Osteogain® is 30 mg/ml, and EMDs are
dissolved with acetic acid to a pH ranging from 4 to 4.5. Nine
rats (18 defects) were randomly assigned to three groups at
each time point (6 defects per group per time point×2 time
points for a total of 12 defects total per group). Each animal
received two types of treatments such as control unfiled de-
fects and NBM alone, or control defects and NBM +
Osteogain®, or NBM and NBM + Osteogain® at each time
point. Nine animals were euthanized at each of the two time
points.
At each time point, 2, 4, and 8 weeks after femur surgery,
animals were sacrificed accordingly. All femurs were harvest-
ed and assigned to micro-computerized tomography (micro-
CT) and histological evaluation.
Micro-CT analysis
The samples were fixed in 4 % formaldehyde for 24 h at room
temperature. A μ-CT imaging system (μ-CT50, Scanco
Medical, Basersdorf, Switzerland) was used to evaluate new
bone formation within the defect region. All samples were
placed in a custom-made holder to ensure that the long axis
of the drilled channel was oriented perpendicular to the axis of
X-ray beam. All samples were calibrated by performing a
scans with identical parameters at 55 kV and 114 mAwith a
thickness of 0.048 mm per slice in medium-resolution mode,
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1024 reconstruction matrix, and 200-ms integration time. A
Gaussian filter (sigma=0.8 and support=1) was used to re-
move noise. The mineralized bone tissue was differentially
segmented to exclude the nonmineralized tissue with a fixed
threshold (value=190). A series of slices starting at a distance
of 1 mm proximal from the end of the growth plate with a
length of 2 mmwere chosen for the evaluation. For evaluation
of bone regeneration within the defect, the central 2-mm-
diameter region of the 2.5-mm-diameter defect was defined
by drawing circular contour as area of measurement per slice,
thus to obtain a consistent volume of interest (VOI) and to
avoid including the native bone margins. All 3D images were
generated by the built-in software of the μ-CT as previously
described [18].
Histological preparation
After fixation, femoral condyles were decalcified in 10 % eth-
ylene diamine tetraacetic acid (EDTA) for 6 weeks,
dehydrated in a series of graded concentration of ethanol from
70 to 100 % and embedded in paraffin. For the paraffin sam-
ples, longitudinal serial sections, 4 μm thick, were cut and
mounted on poly-lysine-coated microscope slides. For de-
scriptive histology, hematoxylin and eosin (H&E) staining,
and Safranin O staining (Sigma #S2255; Sigma-Aldrich, St.
Louis, MO, USA) were performed according to manufac-
turer’s protocol. Specimens were examined under microscop-
ic light using Olympus DP72 microscope (Olympus
Corporation, Tokyo, Japan).
Qualification of the regenerated bone was performed ac-
cording to H&E and Safranin O staining by using Image-Pro
Plus 6.0 software (Media Cybernetics, USA). Areas of newly
formed bone, which acquired a red color in H&E-stained sec-
tions and a bluish-green stain in Safranin O-stained sections,
were delineated manually and then calculated as the percent-
age of new bone area in total cross-sectional area [(bone area/
total area)×100 %] as previously described [19, 23–25]. The
central region of the 2.5-mm-diameter defect was defined by
analyzing a circular contour as area of measurement per slice,
thus to obtain a consistent volume of interest and to avoid
including the native bone margins. To validate the results,
each experiment was repeated at least three times under cali-
brated measurements with the operator blinded to the surgical
technique. Safranin O staining was used to quantitatively in-
vestigate the dynamic degradation process of NBM and NBM
+ Osteogain® particles.
Statistical analysis
All statistical analyses were performed by using Statistical
Package for the Social Sciences (SPSS) 17.0 software
(SPSS, Chicago, IL). Percentage of new bone formation was
expressed as mean±standard deviation and analyzed using
one-way ANOVAwith post hoc test. p<0.05 was considered
as statistically significant difference.
Results
Outcomes by micro-CT
Micro-CT reconstruction was used to visualize the ability of
NBM alone or in combination with Osteogain®-(NBM +
Osteogain®) to influence new bone formation (Fig. 1). As
can be seen from the unfilled control groups, little to no bone
formation was observed at 2 weeks post-implantation (Fig. 1a)
with little new bone formation occurring at the cortex of de-
fects at 4 and 8 weeks post-implantation (Figs. 1b, c). Defects
filled with NBM material initially demonstrate a large filled
area of mineralized tissue since NBM grafting particles are
mineralized (Fig. 1d). Increase in bone formation was ob-
served at 4 and 8 weeks post-implantation (Fig. 1e, f). A
similar trend is observed for defects filled with NBM +
Osteogain® when compared to NBM alone (Fig. 1g–i). Due
to the inability to quantify solely mineralized tissues produced
from new bone (as opposed to the mineralized tissue
contained in NBM particles), a conventional histological ap-
proach was utilized to quantify new bone formation using
morphohistometric analysis (Figs. 2, 3, 4, and 5).
Evaluation of new bone formation
During all experiments, no signs of foreign body inflamma-
tion were observed. At each time point of 2, 4, and 8 weeks,
representative sections of H&E staining and Safranin O stain-
ing are presented in Figs. 2, 3, 4, and 5, respectively, showing
the interface between the tissue and the implanted graft.
After 2 weeks, regenerated new bone and fibrous tissue
were observed in treatment groups filled with NBM or
NBM + Osteogain® (Fig. 2d, g), while the mesenchymal cells
derived from marrow cavity occupied the entire cavity of the
drilled control group (Fig. 2a). No visible difference in new
bone formation was observed between NBM and NBM +
Osteogain® groups at 2 weeks. At 4 weeks post-operation,
minimal bone formation in the control samples was observed
with large voids still present (Fig. 2b). In contrast, at 4 weeks
post-implantation, new bone formation, in both NBMprecoat-
ed with Osteogain® and NBM only filled defects increased
significantly (Fig. 2e, h). In morphology, mature bone lacuna
with the presence of osteocytes in the NBM + Osteogain®-
filled defects were present when compared to NBM alone. At
8 weeks post-operation, the continual progression of new
bone formation in the defects was observed around NBM
particles precoated with Osteogain® (Fig. 2f, i). More newly
formed bone and less fibrous tissue in the NBM +
Osteogain®-filled defect was observed when compared to
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NBM alone at 8 weeks post-implantation. Control defects that
were left unfilled were still void of any substantial amount of
regenerated new bone formation at 8 weeks of healing
(Fig. 2c).
The new bone formation in the defects in all treatment
groups was quantitatively assessed from sections of H&E
staining at each time point of 2, 4, and 8 weeks (Fig. 3).
Significantly much more newly formed bone was observed
around both NBM + Osteogain® and NBM alone when com-
pared to the drilled control group at all time points (p<0.05).
Although no significant difference between NBM +
Osteogain® and NBM alone could be observed at 2 weeks
post-operation, statistical analysis revealed that new bone for-
mation was significantly higher in the NBM + Osteogain®
group at 4 and 8 weeks when compared to NBM alone
(p<0.05).
Safranin O staining was utilized to quantify newly formed
bone by delineating manually and calculating the percentage
of new bone area in total cross-sectional area (Figs. 4 and 5).
Consistent with the quantitative outcomes from sections of
H&E staining, significantly higher new bone formation was
observed in NBM + Osteogain® group when compared to
control unfilled group at each time point (p<0.01). Although
no significant difference between NBM + Osteogain® and
Fig. 2 Representative sections of
H&E staining demonstrate the
healing of defects left unfilled
(a–c), filled with NBM (d–f), or
filled with NBM + Osteogain®
(g–i) at 2, 4, and 8 weeks post-
implantation. More newly formed
bone can be observed in groups
treated with NBM and NBM
+ Osteogain® when compared to
control drill defects at each time
point of 2, 4, and 8 weeks.
Triangle, newly formed bone;
asterisk, filled graft; scale bar,
100 μm
Fig. 1 Micro-CT images
demonstrating the morphology
and defects either left unfilled
(a–c), filled with NBM (d–f), or
filled with NBM + Osteogain®
(g–i). Scale bar, 2 mm
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NBM alone could be observed at 2 weeks post-surgery, sig-
nificantly more newly formed bone was detected in the NBM
+ Osteogain® group at 4 and 8 weeks when compared to
NBM alone (p<0.05).
Discussion
The aim of the present study was to investigate the potential of
Osteogain® in combination with a bone grafting material.
Although the accumulated data until now has demonstrated
strong evidence that EMD enhances periodontal regeneration,
the effects on bone formation has primarily been limited to
intrabony defects [1]. Our group has previously demonstrated
that EMD in combination with a NBM led to an increase in
osteoblast proliferation and differentiation, as well as upregu-
lated a number of key cytokines, growth factors, and their
associated receptors, transcription factors, and osteoblast dif-
ferentiation markers [26, 27]. Despite these in vitro results,
there remains a variety of mixed results over the clinical effi-
cacy of combining Emdogain® with a bone grafting material
for clinical use. While some clinical trials have demonstrated
that the combination provides additional regeneration, others
have failed to show any additional benefit when compared to
bone grafting material used alone or Emdogain® used alone
[9, 12, 14, 28, 29].
Due to these large variation in reported data, our group
recently investigated the adsorption of EMD to grafting parti-
cles and observed significantly altered levels of amelogenin
adsorption to the various grafting materials used [17].
Fig. 3 Percentage of new bone formation measured by analysis of the
H&E staining images. Significantly higher new bone formation was
observed in NBM + Osteogain® group when compared to control
unfilled and NBM alone groups at 4 and 8 weeks post-implantation.
*p<0.05, **p<0.01
Fig. 4 Representative sections of
Safranin O staining
demonstrating the healing of
treatment at 2, 4, and 8 weeks
post-implantation. Triangle,
newly formed bone; asterisk,
filled graft; scale bar, 100 μm
Fig. 5 Percentage of new bone formation measured by analysis of the
Safranin O staining images. Significantly higher new bone formation was
observed inNBM+Osteogain® group when compared to control unfilled
group at each time point and NBM alone group at 4 and 8 weeks post-
implantation. *p<0.05; **p<0.01; ***p<0.001
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Interestingly, the delivery of EMD in liquid formulation im-
proved the adsorption to bone grafting surface when com-
pared to Emdogain® gel. For these reasons, the development
of a new carrier for EMD with better physicochemical prop-
erties was undertaken specifically for combination with bone
grafting material.
In this study, the femur defect model was utilized to fully
characterize the regenerative potential of Osteogain® in com-
bination with a bone grafting material. The femur is an area
with a high number of mesenchymal progenitor cells located
in the bone marrow cavity. Since the effects of EMD target
cells early in their differentiation process [30], the use of the
present model system was sensitive to any regenerative ad-
vantages that Osteogain® could therefore produce. In our pre-
vious study on bone formation using NBM in a femur defect,
we avoided the use of micro-CT to investigate new bone for-
mation as it had an inability to accurately quantify new bone
formation due to high mineral content already present in
NBM. For these reasons, we used a conventional histological
approach to quantify new bone formation. The results from
histological quantification of new bone formation demonstrat-
ed that Osteogain® significantly increased new bone forma-
tion at 4 and 8 weeks post-implantation when compared to
NBM particles alone and drilled control defects.
Furthermore, the combination of Osteogain® + NBM further
provided a higher number of osteocytes embedded within the
new bone matrix around grafting particles.
The key components improving new bone formation in the
present study were the effects of enamel matrix proteins which
have been shown to affect new bone formation under various
models and also utilizing various carrier systems [20, 31–35].
In a classical study by Boyan et al., it was shown that although
EMD does not possess osteoinductive potential, it possessed
osteopromotive benefits when it is combined with active
demineralized freeze-dried bone allografts (DFDBA) and re-
sulted in enhanced bone induction [31]. Furthermore, recent
research from Cochran’s group has provided evidence for an-
giogenic properties of enamel matrix proteins which may sub-
stantially improve vascularization and future wound healing
[36]. Our group has also previously characterized the combina-
tion of EMD delivered in a PGA carrier on new bone formation
in the same animal model where it was also found that EMD
improved new bone formation [6]. Thus, it remains to be eval-
uated what effect Osteogain® may have in the context to the
previously published data and more importantly what effect the
carrier of EMD may have on its osteopromotive potential for
future bone defects with complicated anatomical defects.
Conclusions
Within the limits of the present study, these findings indicate
that the combination of a NBM with Osteogain® was able to
improve bone formation when compared to control unfilled
and NBM alone defects. Furthermore, it was demonstrated
that Osteogain®, a new formation of EMD with better physi-
cochemical properties, was able to significantly enhance ma-
ture new bone formation by demonstrating signs of osteocyte
lacunae embedded within the new bonematrix. Future clinical
research is necessary to fully elucidate the advantages of
Osteogain® in combination with a bone graft material as a
new carrier system for enamel matrix proteins.
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